Initiation Report on Regenerative Medicine Company RepliCel Life Sciences Inc. (TSXV:RP), An Attractive Acquisition Target

RepliCel Life Sciences Inc. (TSXV: RP) is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function such as chronic tendinosis, damaged skin and male pattern baldness.

https://smallcappower.com/wp-content/uploads/cloud.modyocdn.com/uploads/af9a2460f7db11e39f13a565a7ca855e/original/Replicel_Report_20140612_RepliCel-final.pdf